Explore

Trendline Trendline
Arrowhead Pharmaceuticals Reports Strong Fiscal 2026 Second Quarter Results Amidst Growth Initiatives

Arrowhead Pharmaceuticals Reports Strong Fiscal 2026 Second Quarter Results Amidst Growth Initiatives

Arrowhead Pharmaceuticals Reports Strong Fiscal 2026 Second Quarter Results Amidst Growth Initiatives
Trendline Trendline
Arrowhead Pharmaceuticals Reports Strong Growth and New Developments in RNAi Therapeutics

Arrowhead Pharmaceuticals Reports Strong Growth and New Developments in RNAi Therapeutics

Arrowhead Pharmaceuticals Reports Strong Growth and New Developments in RNAi Therapeutics
Trendline Trendline
Arrowhead Pharmaceuticals Reports Strong Fiscal 2026 Second Quarter Results Amid Expanding RNAi Therapeutics

Arrowhead Pharmaceuticals Reports Strong Fiscal 2026 Second Quarter Results Amid Expanding RNAi Therapeutics

Arrowhead Pharmaceuticals Reports Strong Fiscal 2026 Second Quarter Results Amid Expanding RNAi Therapeutics
Trendline Trendline
Nektar Therapeutics Strengthens Financial Position Amidst Development of Lead Biologic Candidate

Nektar Therapeutics Strengthens Financial Position Amidst Development of Lead Biologic Candidate

Nektar Therapeutics Strengthens Financial Position Amidst Development of Lead Biologic Candidate
Trendline Trendline
Sarepta Therapeutics Reports Q1 2026 Financial Results Amidst Strategic Developments

Sarepta Therapeutics Reports Q1 2026 Financial Results Amidst Strategic Developments

Sarepta Therapeutics Reports Q1 2026 Financial Results Amidst Strategic Developments
Trendline Trendline
Compass Pathways to Release Q1 2026 Financial Results and Updates

Compass Pathways to Release Q1 2026 Financial Results and Updates

Compass Pathways to Release Q1 2026 Financial Results and Updates
Trendline Trendline
Soligenix Reports Financial Results and Strategic Updates Amid Clinical Trial Challenges

Soligenix Reports Financial Results and Strategic Updates Amid Clinical Trial Challenges

Soligenix Reports Financial Results and Strategic Updates Amid Clinical Trial Challenges
Trendline Trendline
Zai Lab Reports Q1 2026 Financial Results and Advances Oncology Pipeline

Zai Lab Reports Q1 2026 Financial Results and Advances Oncology Pipeline

Zai Lab Reports Q1 2026 Financial Results and Advances Oncology Pipeline
Trendline Trendline
Madrigal Pharmaceuticals Expands siRNA Pipeline with $1 Billion Deal for MASH Treatment

Madrigal Pharmaceuticals Expands siRNA Pipeline with $1 Billion Deal for MASH Treatment

Madrigal Pharmaceuticals Expands siRNA Pipeline with $1 Billion Deal for MASH Treatment
Trendline Trendline
Madrigal Pharmaceuticals Expands siRNA Portfolio with $1B Arrowhead Deal

Madrigal Pharmaceuticals Expands siRNA Portfolio with $1B Arrowhead Deal

Madrigal Pharmaceuticals Expands siRNA Portfolio with $1B Arrowhead Deal
Trendline Trendline
Arrowhead Pharmaceuticals Licenses MASH Program to Madrigal Pharmaceuticals

Arrowhead Pharmaceuticals Licenses MASH Program to Madrigal Pharmaceuticals

Arrowhead Pharmaceuticals Licenses MASH Program to Madrigal Pharmaceuticals
Trendline Trendline
Madrigal Pharmaceuticals Licenses siRNA Asset for MASH from Arrowhead

Madrigal Pharmaceuticals Licenses siRNA Asset for MASH from Arrowhead

Madrigal Pharmaceuticals Licenses siRNA Asset for MASH from Arrowhead